Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Boehringer Ingelheim
Chinese Patent Office
Fish and Richardson
Daiichi Sankyo

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,071,577

« Back to Dashboard

Which drugs does patent 8,071,577 protect, and when does it expire?

Patent 8,071,577 protects NATAZIA and is included in one NDA. There has been one Paragraph IV challenge on Natazia.

This patent has thirty-eight patent family members in thirty-five countries.

Summary for Patent: 8,071,577

Title:Multi-phase contraceptive preparation based on a natural estrogen
Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.
Inventor(s): Endrikat; Jan (Kirkland, CA), Duesterberg; Bernd (Oberkraemer, DE)
Assignee: Bayer Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/578,771
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
dienogest; estradiol valerate
TABLET;ORAL022252-001May 6, 2010RXYesYes► Subscribe► SubscribeY PREVENTION OF PREGNANCY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,071,577

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2004 019 743Apr 20, 2004
PCT Information
PCT FiledApril 15, 2005PCT Application Number:PCT/EP2005/004022
PCT Publication Date:November 03, 2005PCT Publication Number: WO2005/102247

International Patent Family for Patent: 8,071,577

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Africa200609594► Subscribe
World Intellectual Property Organization (WIPO)2005102247► Subscribe
Uruguay28863► Subscribe
TaiwanI351960► Subscribe
Ukraine83915► Subscribe
El Salvador2006002090► Subscribe
Taiwan200534860► Subscribe
Slovenia1740163► Subscribe
Serbia51434► Subscribe
Portugal1740163► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus